CCR4 CAR-T cell therapy / ARC Therapies, National Cancer Center, University of Pennsylvania - LARVOL DELTA

Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc. (PRNewswire) - "The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric antigen receptor T cell therapy that targets the chemokine receptor CCR4 (CCR4 CAR-T cell therapy) to ARC Therapies Inc...This agreement marks the commencement of ARC Therapies, Inc.'s research and development of a cell therapy targeting T-cell cancers, including adult T-cell leukemia/lymphoma (ATLL), which is prevalent in Japan. Furthermore, the potential application of CCR4 CAR-T cell therapy to solid cancers will also be pursued."

Licensing / partnership • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Solid Tumor